City State Bank Purchases New Shares in Humana Inc. (NYSE:HUM)

City State Bank purchased a new stake in shares of Humana Inc. (NYSE:HUMFree Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 440 shares of the insurance provider’s stock, valued at approximately $153,000.

Other large investors also recently modified their holdings of the company. Gulf International Bank UK Ltd lifted its position in Humana by 0.5% in the 1st quarter. Gulf International Bank UK Ltd now owns 10,313 shares of the insurance provider’s stock valued at $3,575,000 after purchasing an additional 48 shares during the last quarter. Tealwood Asset Management Inc. increased its stake in Humana by 39.1% during the 1st quarter. Tealwood Asset Management Inc. now owns 4,225 shares of the insurance provider’s stock valued at $1,465,000 after buying an additional 1,188 shares during the period. Park Avenue Securities LLC increased its stake in Humana by 6.6% during the 1st quarter. Park Avenue Securities LLC now owns 4,125 shares of the insurance provider’s stock valued at $1,430,000 after buying an additional 256 shares during the period. Banque Cantonale Vaudoise increased its stake in Humana by 25.9% during the 1st quarter. Banque Cantonale Vaudoise now owns 3,111 shares of the insurance provider’s stock valued at $1,079,000 after buying an additional 640 shares during the period. Finally, Polianta Ltd increased its stake in Humana by 40.9% during the 1st quarter. Polianta Ltd now owns 3,100 shares of the insurance provider’s stock valued at $1,074,000 after buying an additional 900 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.5 %

NYSE HUM traded down $1.94 during trading on Friday, reaching $355.48. The company’s stock had a trading volume of 1,633,238 shares, compared to its average volume of 1,161,462. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $42.84 billion, a PE ratio of 22.13, a PEG ratio of 2.09 and a beta of 0.53. The business has a 50-day moving average price of $340.05 and a 200-day moving average price of $354.76. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $9.38 earnings per share. On average, research analysts forecast that Humana Inc. will post 16.07 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.00%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Wall Street Analysts Forecast Growth

Several research firms have commented on HUM. Bank of America raised their target price on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research note on Monday, May 20th. Wells Fargo & Company lowered their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. UBS Group lowered their target price on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Argus cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $360.00 price objective on shares of Humana in a research note on Wednesday, June 12th. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $423.63.

Read Our Latest Stock Report on Humana

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.